The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer

被引:9
作者
Bai, Xiaojing [1 ,2 ]
Jiang, Yumei [1 ,2 ]
Zhang, Xinwei [1 ,2 ]
Wang, Meiyu [3 ]
Tian, Juanhua [1 ]
Mu, Lijun [1 ]
Du, Yuefeng [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China
[2] Minist Educ, Oncol Res Lab, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Imaging, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
基金
中国国家自然科学基金;
关键词
total prostate-specific antigen; free prostate-specific antigen; prostate-specific antigen density; prostate cancer; benign prostatic hyperplasia; FREE ELECTROCHEMICAL IMMUNOSENSOR; DIGITAL RECTAL EXAMINATION; ULTRASOUND-GUIDED BIOPSY; MULTI-PARAMETRIC MRI; MAGNETIC-RESONANCE; HIGH-RISK; NG/ML; PSA; MEN; COMPLICATIONS;
D O I
10.2147/CMAR.S257769
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Methods: From February 2016 to September 2019, data from 620 patients who underwent systematic transrectal ultrasound-guided prostate biopsy (STURS-PB) in our hospital were retrospectively collected, including the PSA levels, the fPSA/TPSA ratio, the PSAD, DRE, TRUS, MP-MRI, prostate volume, and other clinical data. Results: Among the 620 patients, 249 patients were in the PCa group, and 371 patients in the BPH group. The positive puncture rate was 40.16%. The positive predictive values of DRE, TRUS, mpMRI, and TPSA levels for PCa were 39.91%, 39.38%, 64.14%, and 41.57%, respectively; the sensitivity of these parameters was 37.35%, 51.41%, 74.69%, and 57.43%, respectively; and the specificity of these parameters was 62.26%, 46.90%, 71.97%, and 45.82%, respectively. When the TPSA concentration was in the range of 4-20 ng/mL, the positive puncture rate of STURS-PB was 23.18%, with a high rate of misdiagnosis. When the TPSA concentration was in the range of 4-20 ng/mL, the fPSA/ TPSA ratio was 0.15, the PSAD was 0.16, the comprehensive evaluation of PCa was optimal (the sensitivity of these parameters was 88.85% and 84.09%, respectively; the specificity was 80.17% and 67.29%, respectively; the positive predictive value was 57.41% and 51.39%, respectively). When the TPSA concentration >4 ng/mL, the fPSA/TPSA ratio <= 0.15 and the PSAD >= 0.16, the sensitivity, specificity, and correctness index of the PCa and BPH diagnosis were 80.54%, 82.75%, and 67.07%, respectively. Conclusion: When using DRE, TRUS, and MP-MRI to screen for PCa, MP-MRI has a relatively high sensitivity and specificity. Using these three thresholds (TPSA >4 ng/mL combined with an fPSA/TPSA ratio <= 0.15 and a PSAD >= 0.16) is significantly better than using TPSA levels alone for the differential diagnosis of PCa and BPH.
引用
收藏
页码:6821 / 6826
页数:6
相关论文
共 50 条
[41]   Prostate cancer screening with prostate-specific antigen: A guide to the guidelines [J].
Cabarkapa, Sonja ;
Perera, Marlon ;
McGrath, Shannon ;
Lawrentschuk, Nathan .
PROSTATE INTERNATIONAL, 2016, 4 (04) :125-129
[42]   Prostate-Specific Antigen Screening and Mortality from Prostate Cancer [J].
Stephen W. Marcella ;
George G. Rhoads ;
Jeffrey L. Carson ;
Frances Merlino ;
Homer Wilcox .
Journal of General Internal Medicine, 2008, 23 :248-253
[43]   Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan [J].
Kitagawa, Yasuhide ;
Machioka, Kazuaki ;
Yaegashi, Hiroshi ;
Nakashima, Kazufumi ;
Ofude, Mitsuo ;
Izumi, Kouji ;
Ueno, Satoru ;
Kadono, Yoshifumi ;
Konaka, Hiroyuki ;
Mizokami, Atsushi ;
Namiki, Mikio .
ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (06) :833-837
[44]   Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population [J].
Xu, L. ;
Hu, X. ;
Zhu, Y. ;
Lu, J. ;
Xu, Y. ;
Wang, G. ;
Guo, J. .
ANDROLOGIA, 2018, 50 (02)
[45]   Prostate-specific antigen screening: pro [J].
Loeb, Stacy ;
Catalona, William J. .
CURRENT OPINION IN UROLOGY, 2010, 20 (03) :185-188
[46]   The role of free prostate-specific antigen in the diagnosis of prostate cancer [J].
Akdas, A ;
Cevik, I ;
Tarcan, T ;
Turkeri, L ;
Dalaman, G ;
Emerk, K .
BRITISH JOURNAL OF UROLOGY, 1997, 79 (06) :920-923
[47]   Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing [J].
Lavallee, Luke T. ;
Binette, Andrew ;
Witiuk, Kelsey ;
Cnossen, Sonya ;
Mallick, Ranjeeta ;
Fergusson, Dean A. ;
Momoli, Franco ;
Morash, Chris ;
Cagiannos, Ilias ;
Breau, Rodney H. .
MAYO CLINIC PROCEEDINGS, 2016, 91 (01) :17-22
[48]   Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer [J].
Feneley, MR ;
Jan, H ;
Granowska, M ;
Mather, SJ ;
Ellison, D ;
Glass, J ;
Coptcoat, M ;
Kirby, RS ;
Ogden, C ;
Oliver, RTD ;
Badenoch, DF ;
Chinegwundoh, FI ;
Nargund, VH ;
Paris, AMI ;
Britton, KE .
PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (01) :47-52
[50]   Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010 [J].
Naito, Seiji ;
Kakehi, Yoshiyuki ;
Okuyama, Akihiko ;
Imamura, Tomoaki ;
Yasunaga, Hideo ;
Akaza, Hideyuki ;
Hinotsu, Shiro ;
Arai, Yoichi ;
Dokiya, Takushi ;
Egawa, Shin ;
Suzuki, Kazuhiro ;
Koga, Hirofumi ;
Masumori, Naoya ;
Akakura, Koichiro ;
Kawashima, Kiyotaka ;
Okihara, Koji ;
Ito, Kazuto .
INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (10) :830-838